These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

623 related items for PubMed ID: 29402504

  • 1. Novel dual GLP-1/GIP receptor agonists show neuroprotective effects in Alzheimer's and Parkinson's disease models.
    Hölscher C.
    Neuropharmacology; 2018 Jul 01; 136(Pt B):251-259. PubMed ID: 29402504
    [Abstract] [Full Text] [Related]

  • 2. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C.
    Expert Opin Investig Drugs; 2020 Apr 01; 29(4):333-348. PubMed ID: 32175781
    [Abstract] [Full Text] [Related]

  • 3. Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer's disease.
    Ji C, Xue GF, Li G, Li D, Hölscher C.
    Rev Neurosci; 2016 Jan 01; 27(1):61-70. PubMed ID: 26351802
    [Abstract] [Full Text] [Related]

  • 4. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z, Li D, Feng P, Xue G, Ji C, Li G, Hölscher C.
    Eur J Pharmacol; 2017 Oct 05; 812():82-90. PubMed ID: 28666800
    [Abstract] [Full Text] [Related]

  • 5. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P, Zhang X, Li D, Ji C, Yuan Z, Wang R, Xue G, Li G, Hölscher C.
    Neuropharmacology; 2018 May 01; 133():385-394. PubMed ID: 29462693
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders.
    Hölscher C.
    Br J Pharmacol; 2022 Feb 01; 179(4):695-714. PubMed ID: 33900631
    [Abstract] [Full Text] [Related]

  • 9. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L, Zhang L, Li Y, Li L, Melchiorsen JU, Rosenkilde M, Hölscher C.
    J Parkinsons Dis; 2020 Feb 01; 10(2):523-542. PubMed ID: 31958096
    [Abstract] [Full Text] [Related]

  • 10. A novel GLP-1/GIP dual receptor agonist protects from 6-OHDA lesion in a rat model of Parkinson's disease.
    Jalewa J, Sharma MK, Gengler S, Hölscher C.
    Neuropharmacology; 2017 May 01; 117():238-248. PubMed ID: 28223210
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A novel dual GLP-1 and GIP receptor agonist is neuroprotective in the MPTP mouse model of Parkinson's disease by increasing expression of BNDF.
    Ji C, Xue GF, Lijun C, Feng P, Li D, Li L, Li G, Hölscher C.
    Brain Res; 2016 Mar 01; 1634():1-11. PubMed ID: 26453833
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Neuroprotective effects of a triple GLP-1/GIP/glucagon receptor agonist in the APP/PS1 transgenic mouse model of Alzheimer's disease.
    Tai J, Liu W, Li Y, Li L, Hölscher C.
    Brain Res; 2018 Jan 01; 1678():64-74. PubMed ID: 29050859
    [Abstract] [Full Text] [Related]

  • 15. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C.
    Sheng Li Xue Bao; 2014 Oct 25; 66(5):497-510. PubMed ID: 25331995
    [Abstract] [Full Text] [Related]

  • 16. Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
    Yang X, Feng P, Ji R, Ren Y, Wei W, Hölscher C.
    Expert Opin Ther Targets; 2022 May 25; 26(5):445-460. PubMed ID: 35584372
    [Abstract] [Full Text] [Related]

  • 17. A novel dual GLP-1 and GIP incretin receptor agonist is neuroprotective in a mouse model of Parkinson's disease by reducing chronic inflammation in the brain.
    Cao L, Li D, Feng P, Li L, Xue GF, Li G, Hölscher C.
    Neuroreport; 2016 Apr 13; 27(6):384-91. PubMed ID: 26918675
    [Abstract] [Full Text] [Related]

  • 18. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C.
    Recent Pat CNS Drug Discov; 2010 Jun 13; 5(2):109-17. PubMed ID: 20337586
    [Abstract] [Full Text] [Related]

  • 19. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J, Blunt E, Gupta D, Edison P.
    Ageing Res Rev; 2023 Aug 13; 89():101979. PubMed ID: 37328112
    [Abstract] [Full Text] [Related]

  • 20. [GLP-1/GIP/Gcg receptor Triagonist improves the cognitive behaviors in triple-transgenic mice of Alzheimer's disease].
    Jiao JJ, Hölscher C, Li T, Dong XF, Qu XS, Cao Y, Wu MN, Wang ZJ, Qi JS.
    Sheng Li Xue Bao; 2017 Apr 25; 69(2):135-145. PubMed ID: 28435972
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.